February 14, 2006 – AstraZeneca slipped lower after withdrawing its controversial blood thinning drug, Exanta, from the market; GlaxoSmithKline bought the research institute of Pliva in a deal valued at up to $50 million; GlaxoSmithKline also reported that the FDA has begun its review of a new antibiotic called Retapamulin; QLT reported its experimental drug for benign prostatic hyperplasia failed a Phase II trial; Genmab in-licensed angiogenesis targets from an Australian biotech, Bionomics Limited; Nektar said the FDA gave orphan drug designation to its inhaled drug for lung infections; and Inhibitex has begun its “rolling” filing for Veonate, an antibiotic for very low birth-weight infants. The Centient Biotech 200™ was up a big 46 points at 3891.97, a gain of 1.2%. More details...
